Browse every published article, from the latest research to earlier analysis. Use the page numbers below to explore the complete archive.
A small specialist-unit study shows why a medication count alone cannot explain prescribing quality.
A two-country registry analysis associated benzodiazepine-related treatment with worse outcomes in schizoaffective disorder.
A claims-based endometriosis study identifies benzodiazepine co-prescribing within a broader pattern of chronic opioid treatment.
A perioperative probe study found that acute inflammation changed enzyme activity differently across pathways and postoperative days.
A small clinical interaction study found substantially lower midazolam exposure after a week of metamizole.
A large endoscopy analysis associated multi-drug sedation with adverse events, while emphasizing that patient and procedural factors also mattered.
A retrospective comparison found different palliative medication patterns in interstitial pneumonia and lung cancer.
A toxicant experiment found protection against lethal and tonic seizure outcomes without eliminating all seizure activity.
A palliative-care cohort found an association between benzodiazepine treatment and catheterization, but catheter use had several clinical drivers.
A shared preference for buccal midazolam did not produce a uniform approach to prescribing, training or withdrawal of rescue plans.
Remaining on treatment, responding and becoming seizure-free were related but separately counted outcomes.
The uneventful course reflected a complete anesthetic and hematologic strategy in one high-risk patient.
The observed change after restrictions was compatible with a policy effect, while leaving other time-related explanations unresolved.
The stable measurements followed a single added dose in an already anesthetized group, without a parallel comparator.
The midazolam result addressed enzyme-mediated exposure under a tested schedule, rather than the antitumor effect of the benzodiazepine.
A questionnaire-based dependence classification adds patient experience, but remains distinct from a complete diagnosis of misuse or addiction.
The efficiency result came from a randomized diagnostic-endoscopy population, with follow-up ending at discharge.
An electrographic response to a benzodiazepine did not alone resolve the diagnosis of seizure activity in this poisoning case.
The cerebral-protection hypothesis was tested in induced rat injury and cultured rat neurons.
Earlier measured awakening after the switch was distinct from an unrestricted earlier discharge policy.
The interaction study found opposite exposure directions for the parent drug and two measured metabolites.
An early analgesic advantage did not translate into a demonstrated difference in the twenty-four-hour total.
The crude mortality difference between first-line treatment groups did not persist as an independent association after adjustment.
A large review found stronger evidence for some patient-reported outcomes than for others, so one certainty label cannot cover the entire result.
Onset and recovery moved in opposite directions, while recovery-unit time remained similar.
The recovery meta-analysis did not find that remimazolam improved every postoperative outcome.
The declining dose estimates with age describe a research endpoint under a specified opioid-containing protocol.
The pediatric adjunct study included a later behavioral assessment, which is different from simply measuring how quickly children woke up.
A sedative comparison during blind nasal intubation also reflects the demands of a specific airway technique.
A prevalence association does not establish that medication exposure preceded cancer.